Short Interest in Microbot Medical Inc. (NASDAQ:MBOT) Increases By 16.7%

Microbot Medical Inc. (NASDAQ:MBOT) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 206,300 shares, a growth of 16.7% from the August 15th total of 176,800 shares. Based on an average daily volume of 180,900 shares, the short-interest ratio is presently 1.1 days.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Microbot Medical in a report on Monday, June 3rd.

Hedge Funds Weigh In On Microbot Medical

An institutional investor recently bought a new position in Microbot Medical stock. Armistice Capital LLC bought a new position in Microbot Medical Inc. (NASDAQ:MBOT) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 300,000 shares of the biotechnology company’s stock, valued at approximately $492,000. Armistice Capital LLC owned about 2.56% of Microbot Medical at the end of the most recent quarter. Hedge funds and other institutional investors own 16.30% of the company’s stock.

Microbot Medical Stock Performance

Shares of Microbot Medical stock traded down $0.02 on Tuesday, reaching $0.94. 239,035 shares of the company were exchanged, compared to its average volume of 1,025,557. The firm has a market cap of $14.96 million, a price-to-earnings ratio of -1.05 and a beta of 1.64. Microbot Medical has a 1-year low of $0.82 and a 1-year high of $2.35. The company’s 50-day moving average is $0.98 and its two-hundred day moving average is $1.04.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). As a group, sell-side analysts forecast that Microbot Medical will post -0.66 earnings per share for the current year.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.